A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

NSCLC Stage IIIB~IV

Interventions

DRUG

Atezolizumab Injection; bevacizumab Injection

a PD-L1 inhibitor; anti-angiogenesis

Trial Locations (1)

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER